These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38244585)
1. Wang FM; Xu LQ; Zhang ZC; Guo Q; Du ZP; Lei Y; Han X; Wu CY; Zhao F; Chen JL Aging (Albany NY); 2024 Jan; 16(2):1605-1619. PubMed ID: 38244585 [TBL] [Abstract][Full Text] [Related]
2. Prognostic and immunological potential of PPM1G in lung adenocarcinoma. Yin R; Qu L; Wang Z; Tang J; Gu H; Wang X; Yang D; Du P; Dong M Mol Med Rep; 2023 Aug; 28(2):. PubMed ID: 37387407 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma. Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484 [TBL] [Abstract][Full Text] [Related]
4. Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma. Hu S; Wang F; Yang J; Xu X Math Biosci Eng; 2023 Sep; 20(10):18063-18082. PubMed ID: 38052548 [TBL] [Abstract][Full Text] [Related]
5. High Expression of Chen Y; Zhou M; Gu X; Wang L; Wang C Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850 [TBL] [Abstract][Full Text] [Related]
6. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches. Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S PeerJ; 2023; 11():e16166. PubMed ID: 37790630 [TBL] [Abstract][Full Text] [Related]
7. Identification of Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
9. Bioinformatics and experimental approach identify lipocalin 2 as a diagnostic and prognostic indicator for lung adenocarcinoma. Li A; Zhang K; Zhou J; Li M; Fan M; Gao H; Ma R; Gao L; Chen M Int J Biol Macromol; 2024 Jun; 272(Pt 2):132797. PubMed ID: 38848833 [TBL] [Abstract][Full Text] [Related]
10. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle. Tang X; Zhou H; Liu Y Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
12. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities]. Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328 [TBL] [Abstract][Full Text] [Related]
13. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
14. Overexpression and diagnostic significance of INTS7 in lung adenocarcinoma and its effects on tumor microenvironment. Li X; Yao Y; Qian J; Jin G; Zeng G; Zhao H Int Immunopharmacol; 2021 Dec; 101(Pt B):108346. PubMed ID: 34781123 [TBL] [Abstract][Full Text] [Related]
15. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573 [TBL] [Abstract][Full Text] [Related]
16. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma. Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Wang W; Ren S; Wang Z; Zhang C; Huang J Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070 [TBL] [Abstract][Full Text] [Related]
18. Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression. Liu Y; Xie P; Jiang D; Liu J; Zhang J; Bian T; Shi J Front Immunol; 2020; 11():568440. PubMed ID: 33424830 [TBL] [Abstract][Full Text] [Related]
19. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD. Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]